AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04290533 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active High Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: TDCS is a non-invasive neuromodulation technique that modulates membrane potentials by means of small electrical currents. Electrical currents induced by tDCS electrodes produce an electrical field that modulates the excitability of brain areas. In the present HD-tDCS montage, one anodal electrode and four return electrodes are applied. Hereby, the anodal electrode modulates the excitability of the targeted area, whereas the other 4 electrodes return electrical currents that flow away from that area. Direct currents will be transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2) with a current intensity of 1.5 mA. The HD-tDCS session will last for 20 minutes in total, with a 60 sec ramp at the beginning and end of the session. The electrodes will be filled with conductive gel and plugged into an EEG cap, with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system).
Study NCT04290533 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham High Definition transcranial Direct Current Stimulation (HD-tDCS)
Description: For the sham-condition, the placement of the electrodes was identical to active HD-tDCS stimulation with the anode placed over Fz and the four return electrodes over Fp1, Fp2, F7, and F8 (10-20 system). The direct current, also transmitted through 5 circular PiStim electrodes of 3.14cm2 (Neuroelectrics, Barcelona, Spain; current density=0.32 mA/cm2), was increased in a ramp-like fashion over 60 seconds until it reached 1.5 mA. Directly after ramp-up, the current intensity was gradually switched off over 60 seconds, followed by 20 minutes without active stimulation. Sham procedures for tDCS mimic the transient skin sensation at the beginning of active HD-tDCS, without producing any conditioning effects on the brain. Consequently, participants are reliably blinded for sham tDCS.
Study NCT04075396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: Participants will receive Lazertinib tablets once daily.
Study NCT03079518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose
Description: single shot infusion
Study NCT03079518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood withdrawal
Description: for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
Study NCT01179750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasonic Coagulating Shears
Description: comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
Study NCT01532414 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule taken one time daily for 3 months
Study NCT01278238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
Study NCT01278238 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lower limb compression
Description: Tight bandaging of lower extremity up to hips with compression bandages
Study NCT01278238 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Neither phenylephrine nor lower limb bandaging
Study NCT01961297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium oxybate
Description: Sodium oxybate
Study NCT04343430 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion (ASCEND, NYHA and Ambrosy Score) will be performed before discharge from hospital
Study NCT04343430 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography
Description: Cardio-pulmonary, peritoneal, jugular and renal Doppler ultrasounds and liver elastography will be performed before discharge from hospital
Study NCT04343430 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biological: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample collection will be performed before discharge from hospital
Study NCT04343430 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Telephone interview
Description: Telephone interview will be performed at 3, 12 months and 24 months after discharge from Hospital
Study NCT04343430 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Kansas City Cardiomyopathy Questionnaire (KCCQ)
Description: Questionnaire centered on patient's quality of life at discharge and 3, 12 and 24 months after discharge
Study NCT01651819 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Urological physical therapy
Description: Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
Study NCT00752739 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: selenium
Description: Given orally
Study NCT00752739 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study NCT06328270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ozone - oxygen Therapy
Description: Ozone gas is a structurally unstable molecule that contains three oxygen atoms.
Study NCT02848105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VPA
Description: Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
Study NCT00166244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.~Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma.
Study NCT02388360 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: topical prostaglandin analogs
Study NCT02851693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) with Vivosight
Description: OCT used is Vivosight for diagnosis
Study NCT02851693 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography (OCT) with Skintell
Description: OCT used is Skintell for diagnosis
Study NCT02187692 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCT
Description: The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
Study NCT03352726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBV712 IHRP
Description: DBV712 Solution for Skin Prick Test
Study NCT04142255 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: FMT administration starts on the first week of enrollment. Age-based dose of FMT is taken once a day for the first three days of the first week. Then once a week for 3 weeks.
Study NCT02101138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Description: Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
Study NCT02238769 — intervention group
Intervention type: DEVICE
Intervention: 18F-FluoroethylCholine PET
Description: 18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
Study NCT02278666 — intervention group
Intervention type: PROCEDURE
Intervention: aortic valve replacement
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve
Study NCT02278666 — intervention group
Intervention type: DEVICE
Intervention: biological prosthetic valve
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve
Study NCT02278666 — intervention group
Intervention type: DEVICE
Intervention: Mechanical valve
Description: aortic valve replacement with either biological prosthetic valve or mechanical valve
Study NCT02940249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Apple polyphenols
Description: Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
Study NCT02940249 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01670474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA (2mg/2mL) actilysis
Description: At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
Study NCT01670474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA (2mg/2mL) actilysis
Description: At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
Study NCT01670474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
Study NCT01670474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rt-PA
Description: At the first catheter dysfunction (Qb \< 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
Study NCT01593020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
Study NCT01593020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: 1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
Study NCT06328270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: 1 ml betamethasone
Study NCT00097227 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.~A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B.
Study NCT01593020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
Study NCT01593020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
Study NCT01593020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
Study NCT01593020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
Study NCT04251442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OrthoSensor Verasense Technology
Description: IOS is used to send real time information to a monitor within the operating room that assists your surgeon in making decisions about the balance of the ligaments in your knee and the proper insertion of implants.
Study NCT02907905 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: capillary sampling
Description: After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.~The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results
Study NCT03411941 — intervention group
Intervention type: DRUG
Intervention: Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
Description: IVT(Intravitreal) aflibercept treatment in routine clinical practice.
Study NCT02754596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intraocular Implant, high elution
Description: Surgical implant placed within the eye to elute travoprost.
Study NCT02754596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intraocular Implant, low elution
Description: Surgical implant placed within the eye to elute travoprost
Study NCT02754596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution, 0.5%
Description: Instillation of one drop of timolol in the study eye twice daily
Study NCT00756067 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccine GSK2189241A
Description: Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
Study NCT00756067 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumo 23™
Description: One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
Study NCT03828968 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: bladder scan
Description: Measurement of vesical volume by bladder scan
Study NCT00097227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
Study NCT00097227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
Study NCT00704769 — intervention group
Intervention type: DRUG
Intervention: Desloratadine (assigned by investigator as part of normal practice)
Description: Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
Study NCT03874819 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medium cut-off dialyzer
Description: Treatment using a Medium Cut-Off Dialyzer
Study NCT03874819 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-flux dialyzer
Description: Treatment using a high-flux dialyzer
Study NCT00575419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: * Dose Level 1: 150 mg/kg/day~* Dose Level 2: 300 mg/kg/day~* Dose Level 3: 600 mg/kg/day~* Dose Level 4: 900 mg/kg/day~* Dose Level 5: 1200 mg/kg/day
Study NCT04527536 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neonatal hyperbilirubinemia
Description: Neonatal hyperbilirubinemia：The total serum bilirubin exceeds the 95th percentile of the Bhutani neonatal hourly bilirubin nomogram.
Study NCT01400958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nuvigil®
Description: Nuvigil® 150 mg/day x 42 days THEN, No More Drug
Study NCT01400958 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo x 42 days; THEN, No More Placebo
Study NCT01118754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-101 ophthalmic suspension
Description: Ophthalmic suspention; QID
Study NCT01118754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-101 ophthalmic suspension
Description: Ophthalmic suspention; QID
Study NCT01118754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-101 ophthalmic suspension
Description: Ophthalmic suspension; QID
Study NCT01118754 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: DE-101 ophthalmic suspension vehicle
Description: ophthalmic suspension vehicle; QID
Study NCT01890733 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Best Repair of torn Rotator Cuff
Study NCT01890733 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: InSpace™ system
Study NCT00715949 — intervention group
Intervention type: OTHER
Intervention: Immediate Post-concussion Assessment and Cognitive Testing
Description: ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
Study NCT01406730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: 16 week of periodized progressive running exercise 2-4 times/week
Study NCT03053713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean diet pattern
Description: Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
Study NCT03053713 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Habitual diet (control)
Description: Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
Study NCT02790450 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Description: 1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
Study NCT00424099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: 5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
Study NCT00424099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nursing Telephone Intervention
Description: Call from study nurse 3 times weekly to ask about side effects and other symptoms.
Study NCT00424099 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nursing Telephone Intervention
Description: Call from study nurse 3 times weekly to ask about side effects and other symptoms.
Study NCT00424099 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
Study NCT00424099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
Study NCT00424099 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non NTI
Description: Non NTI are calls from research staff 3 times weekly.
Study NCT03377452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and the Behavioral Changes to Treat Sleep Apnea (ACB-SA)
Description: Six session manual-based program using acceptance-and commitment therapy (ACT) framework, behavior change strategies and sleep apnea/PAP education. Sessions delivered in individual format, either in-person or via telehealth.
Study NCT03377452 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-directive sleep apnea education control
Description: Six session sleep apnea and PAP education program. Sessions delivered in individual format, either in-person or via telehealth.